A scientist who is a cancer patient decided to cure herself with oncolytic viruses. She has now been cancer-free for four years.

AI trained on Swedish registry data predicts melanoma risk five years ahead with 73% accuracy, enabling targeted screening of high‑risk groups and more efficient use of healthcare resources.

Scientists designed CRISPR to self-destruct tumor cells carrying p53 mutations, a target no drug has ever reached. A Nature paper details the approach for ovarian, pancreatic, and lung cancers.

A custom treatment built from each patient's tumor mutations, given with an existing immunotherapy, met its main goals in a large late-stage study and relies on computational ranking of targets.

New translational data demonstrate Pelareorep's ability to activate tumor-specific immune responses in KRAS-mutant pancreatic and breast cancers.

UBC Okanagan scientists have unlocked the enzymatic pathway behind mitraphylline, a rare plant‑based anticancer molecule, enabling a sustainable production route for future therapies.

UCLA researchers discovered that creatine fuels the immune system's cancer-fighting command cells, opening a surprising new avenue for future immunotherapies.

The work investigates whether natural vibration frequencies can help p53 activate specific gene groups to support dna repair and limit cancer risk.

Ben Goertzel and Kennedy Schaal shed light on the connection between flies, cancer, and human genetics, uncovering remarkable similarities and implications for research.

Dr. Axel Schumacher announces a partnership with Aerion Biosciences for using AI technology to develop screening mechanisms able to detect lung cancer early enough to treat it successfully.